Ra pharmaceuticals, inc. (RARX)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15
Cash flows from operating activities
Net loss

-102,688

-64,943

-54,439

-28,864

-13,943

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

1,619

1,597

1,524

1,274

897

Non-cash operating lease expense

561

-

-

-

-

Stock-based compensation

14,045

7,695

5,573

1,026

152

Non-cash interest expense with stockholders

-

-

-

-

109

Loss on debt extinguishment with stockholders

-

-

-

-

-602

Accretion of discount and debt issuance costs of convertible notes with stockholders

-

-

-

-

-50

Change in fair value of preferred stock tranche rights

-

-

-

960

-74

Other, net

-74

24

-8

-84

95

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

6,985

49

1,023

890

392

Accounts payable and accrued expenses

7,020

1,126

2,012

4,018

1,102

Operating lease liabilities

-1,007

-

-

-

-

Deferred rent

-

329

415

-2,389

-517

Deferred revenue

-

-

-

-1,862

-883

Other, net

-

19

19

-22

59

Net cash used in operating activities

-87,361

-54,946

-46,779

-21,843

-12,017

Purchase of property and equipment

865

1,034

1,412

5,105

331

Other, net

-

-

-

-9

-1

Net cash used in investing activities

-865

-1,034

-1,412

-5,096

-330

Cash flows from financing activities
Proceeds from common stock offering, net of underwriter discounts

140,530

195,014

-

98,009

-

Payment of common stock offering costs

540

403

176

2,110

-

Payments related to restricted stock units vesting

583

-

-

-

-

Proceeds from issuance of preferred stock

-

-

-

29,250

24,142

Payment of preferred stock issuance costs

-

-

-

22

193

Proceeds from issuance of convertible notes with stockholders

-

-

-

-

5,000

Proceeds from disgorgement of stockholder's short-swing profits

-

-

670

-

-

Proceeds from exercises of stock options and ESPP shares

3,989

784

266

109

84

Other, net

-

26

-

-

-5

Net cash provided by financing activities

143,396

195,421

760

125,236

29,028

Net change in cash, cash equivalents and restricted cash

55,170

139,441

-47,431

98,297

16,681

Noncash operating activity:
Operating lease liabilities arising from obtaining right-of-use assets

682

-

-

-

-

Noncash investing and financing activity:
Conversion of redeemable convertible preferred stock into common stock

-

-

-

86,483

-

Gain on extinguishment of Series A redeemable convertible preferred stock

-

-

-

-

1,673

Common stock offering costs incurred but unpaid at period end

35

278

139

232

-

Changes in liabilities and prepaid expenses related to fixed asset additions

329

33

124

127

484